Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis P Garrison

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2009
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancerLouis P Garrison, David L Veenstra
Pharmacoeconomics|June 8, 2002
Estimating the effect of changes in body mass index on health state preferencesZafar Hakim, Anne Wolf, Louis P Garrison
Health Affairs (Project Hope)|September 13, 2006
Linking pharmacogenetics-based diagnostics and drugs for personalized medicineLouis P Garrison, M J Finley Austin
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 6, 2022
Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic EfficiencyLouis P Garrison, Boshen Jiao, Omar Dabbous
Expert Review of Pharmacoeconomics & Outcomes Research|November 14, 2013
Differential pricing of new pharmaceuticals in lower income European countriesZoltán Kaló, Lieven Annemans, Louis P Garrison
Journal of Managed Care & Specialty Pharmacy|April 28, 2021
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapiesLouis P Garrison, Boshen Jiao, Omar Dabbous
JAMA Health Forum|January 23, 2026
Stakeholder Engagement for Hepatitis C Virus EliminationLouis P Garrison, Bruce C M Wang
Health Affairs (Project Hope)|May 9, 2007
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysisLouis P Garrison, Adrian Towse, Brian W Bresnahan
Pharmacoeconomics|July 12, 2017
Performance-Based Risk-Sharing Arrangements: An Updated International ReviewJosh J Carlson, Shuxian Chen, Louis P Garrison
Journal for Immunotherapy of Cancer|September 5, 2019
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of CancerPeter Paul Yu, Omar Eton, Louis P Garrison
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 24, 2009
The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancerLouis P Garrison, David L Veenstra
Pharmacoeconomics|June 8, 2002
Estimating the effect of changes in body mass index on health state preferencesZafar Hakim, Anne Wolf, Louis P Garrison
Health Affairs (Project Hope)|September 13, 2006
Linking pharmacogenetics-based diagnostics and drugs for personalized medicineLouis P Garrison, M J Finley Austin
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 6, 2022
Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic EfficiencyLouis P Garrison, Boshen Jiao, Omar Dabbous
Expert Review of Pharmacoeconomics & Outcomes Research|November 14, 2013
Differential pricing of new pharmaceuticals in lower income European countriesZoltán Kaló, Lieven Annemans, Louis P Garrison
Journal of Managed Care & Specialty Pharmacy|April 28, 2021
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapiesLouis P Garrison, Boshen Jiao, Omar Dabbous
JAMA Health Forum|January 23, 2026
Stakeholder Engagement for Hepatitis C Virus EliminationLouis P Garrison, Bruce C M Wang
Health Affairs (Project Hope)|May 9, 2007
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysisLouis P Garrison, Adrian Towse, Brian W Bresnahan
Pharmacoeconomics|July 12, 2017
Performance-Based Risk-Sharing Arrangements: An Updated International ReviewJosh J Carlson, Shuxian Chen, Louis P Garrison
Journal for Immunotherapy of Cancer|September 5, 2019
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of CancerPeter Paul Yu, Omar Eton, Louis P Garrison
Pageof 19